Wloclawek

Researchers are evaluating the safety and effects of different doses of a new medicine called NNC0519-0130 in people living with chronic kidney disease, some of whom have type 2 diabetes and are overweight or obese. This Phase 2 study also compares NNC0519-0130 to semaglutide, an already prescribed medicine, and a placebo to see how they may improve kidney function. Participants will be randomly assigned to receive once-weekly subcutaneous injections of NNC0519-0130 with a fixed dose escalation until reaching a maintenance dose, semaglutide with a similar dosing schedule, or a placebo matching NNC0519-0130. The treatment period lasts up to 43 weeks with several dosing schemes and groups. During the study, participants will have their kidney function monitored through urine albumin-to-creatinine ratio changes at weeks 12, 24, and 36. Other assessments include estimated glomerular filtration rate, body weight changes, waist circumference, blood pressure, and glycated hemoglobin levels. Safety will be evaluated by tracking adverse events throughout the trial duration. Participants will be regularly assessed to understand the medicines effects and safety.

Researchers are evaluating the safety and effects of a new medicine called NNC0487-0111 in people who have Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF and excess body weight. This phase 3 clinical trial aims to find out if NNC0487-0111 is safe and effective for treating these conditions compared to a placebo. Participants have HFpEF or HFmrEF and a body mass index of 30 or above. The study is sponsored by Novo Nordisk AS and uses a randomized, quadruple-masked design. Participants will receive either NNC0487-0111 or a matching placebo by injection under the skin once a week. The NNC0487-0111 is given in increasing doses over time. The study is parallel in design, meaning participants are randomly assigned to one of the two groups and receive that treatment throughout the trial. This treatment period extends for up to about 165 weeks. The study evaluates the time to certain heart failure events, hospitalizations, cardiovascular deaths, and other major cardiovascular events. During the study, participants will be monitored regularly to assess heart failure outcomes and kidney function, as well as quality of life using questionnaires like the Kansas City Cardiomyopathy Questionnaire. Safety and effectiveness are assessed through hospital visits, heart failure event tracking, and blood tests including kidney function and blood sugar levels. The total participation spans over three years, with ongoing evaluations to measure the time to heart failure events and cardiovascular outcomes. Participants receive close medical monitoring throughout the study period.

Researchers are evaluating orforglipron to measure its effects on cardiovascular outcomes in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This phase 3 study aims to compare orforglipron with a placebo to better understand its impact on major cardiovascular events over about five years. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally along with standard care. The study is double-blinded, meaning neither participants nor researchers will know who receives the active drug or placebo during the trial period. During the study, participants will be followed for around five years, with researchers monitoring the time to the first major cardiovascular event and additional outcomes such as cardiovascular and kidney events, changes in kidney function measured by eGFR, and the onset of type 2 diabetes. The study includes regular assessments to track these outcomes and ensure participant safety throughout the long-term follow-up.

This research aims to evaluate whether BI 3032950 helps adults aged 18 to 80 years who have moderate to severe ulcerative colitis and have not responded well or stopped previous treatments. The study is a Phase IIa clinical trial sponsored by Boehringer Ingelheim, focusing on the treatments efficacy, safety, and tolerability for this condition. The trial has two parts In Part A, participants receive BI 3032950 as an intravenous infusion every 4 weeks for 12 weeks. After this period, doctors assess improvements in symptoms and then participants move to Part B, where BI 3032950 is given as a subcutaneous injection every 4 weeks. Participants who show clinical response after 12 weeks can continue this subcutaneous treatment for up to 2 years. Participants visit their doctors every 4 weeks for assessments including symptom checks, blood and stool sample collections, and endoscopies to examine the colon. Researchers monitor the participants health and any side effects throughout the study. The main outcome measured is clinical remission using the modified Mayo Score up to Week 12, along with other measures like endoscopic remission and treatment-emergent adverse events.

Researchers are studying tulisokibart also known as MK-7240, a medicine designed to treat active, moderate to severe Crohns disease CD and ulcerative colitis UC. This extension study allows people who have already received tulisokibart in certain previous studies for CD or UC to continue in order to learn more about the long-term safety and how well people tolerate this medicine. The study is led by Merck Sharp & Dohme LLC and is in Phase 3. Participants receive tulisokibart through injections under the skin. There are different groups receiving either low or high doses, with some doses given openly and others in a blinded manner where participants and researchers do not know which dose is given. This allows comparison of how different doses work and their safety over time. The study lasts up to approximately 378 weeks, which is about 7 years. During the study, participants are regularly monitored for any side effects and whether they stop treatment due to these effects. Researchers also assess disease symptoms such as remission rates using scores for Crohns disease and ulcerative colitis at week 364. Participants undergo clinical evaluations and safety checks throughout the study period. The goal is to understand the long-term effects and safety of tulisokibart while participants continue their usual care.